维立西呱联合沙库巴曲缬沙坦钠治疗慢性心衰的效果  

Efficacy of vericiguat combined with sacubitril valsartan sodium in treatment of chronic heart failure

作　　者：章雨阳 洪艳玲[1] 田茂[2] 蔡佩佩 寇艳[1] Zhang Yu-yang;Hong Yan-ling;Tian Mao;Cai Pei-pei;Kou Yan(Department of Electrocardiography,Luzhou People’s Hospital,Luzhou 646010,China;Department of Cardiology,Luzhou People’s Hospital,Luzhou 646010,China)

机构地区：[1]泸州市人民医院心电图科,泸州646010 [2]泸州市人民医院心内科,泸州646010

出　　处：《中国药物应用与监测》2024年第5期523-527,共5页Chinese Journal of Drug Application and Monitoring

基　　金：四川医院管理和发展研究中心2021年度科研项目(SCYG2021-16)。

摘　　要：目的 观察维立西呱联合沙库巴曲缬沙坦钠治疗慢性心力衰竭(CHF)的效果及对心电图参数、临床终点事件发生率的影响。方法 选取2022年6月至2024年1月于泸州市人民医院治疗的CHF患者104例,采用随机数字表法将患者分为对照组与联合组,对照组52例采用沙库巴曲缬沙坦钠治疗,联合组52例采用维立西呱联合沙库巴曲缬沙坦钠治疗,两组均持续治疗3个月,观察并比较两组患者治疗效果、心电图参数(QRS间期、Te-Tp间期)、心率、左心室射血分数(LVEF)、N末端B型利钠肽前体(NT-proBNP)以及临床终点事件发生率。结果 联合组治疗总有效率为94.23%(49/52),高于对照组的80.77%(42/52),差异有统计学意义(χ^(2)=4.308,P<0.05)。治疗后,联合组和对照组的QRS间期、Te-Tp间期分别为(97.75±10.62) ms、(66.52±11.37) ms和(106.34±10.86) ms、(84.48±13.69) ms,组间差异有统计学意义(t=4.078,t=7.278,均P<0.001)。治疗后,联合组和对照组的心率分别为(73.41±8.13)次·min^(-1)和(75.54±8.26)次·min^(-1),差异无统计学意义(t=1.325,P>0.05)。治疗后,联合组和对照组的LVEF、NT-proBNP分别为(52.47±7.87)%、(1 120.57±81.69) pg·mL^(-1)和(46.35±7.49)%、(1 338.62±84.73) pg·mL^(-1),差异有统计学意义(t=4.062,t=13.360,均P<0.001)。联合组临床终点事件总发生率为13.46%(7/52),低于对照组的26.92%(14/52),差异有统计学意义(χ^(2)=7.675,P<0.05)。结论 维立西呱联合沙库巴曲缬沙坦钠治疗CHF患者相较于单纯的沙库巴曲缬沙坦钠疗效更好,能有效改善心电图参数、LVEF与NT-proBNP,并降低临床终点事件发生率。Objective To investigate the efficacy of vericiguat combined with sacubitril valsartan sodium in the treatment of chronic heart failure(CHF)and its impact on electrocardiogram parameters and the incidence of clinical endpoint events.Methods A total of 104 patients with CHF admitted to Luzhou People's Hospital from June 2022 to January 2024 were selected and divided into the control group(n=52)and the combination group(n=52)using the randomized numerical table method.The patients in the control group were treated with sacubitril valsartan sodium and those in the combination group with vericiguat and sacubitril valsartan sodium.All the 104 patients were treated for 3 months.The therapeutic effects,electrocardiogram parameters(QRS interval,Te-Tp interval and heart rate(HR)),left ventricular ejection fraction(LVEF),N-terminal pro B-type natriuretic peptide(NT-proBNP),and the incidence of clinical endpoint events were observed and compared between the two groups.Results The total effective rate in the combined group was 94.23%(49/52),which was higher than that of 80.77%(42/52)in the control(χ^(2)=4.308,P<0.05).After treatment,the QRS interval and Te-Tp interval were significantly higher in the combined group than in the control((97.75±10.62)ms vs(66.52±11.37)ms,(106.34±10.86)ms vs(84.48±13.69)ms)(t=4.078,7.278,both P<0.001).The HR was(73.41±8.13)beats·min-1 in the combined group and(75.54±8.26)beats·min-1 in the control group,showing no statistically significant difference(t=1.325,P>0.05).The LVEF and NT-proBNP were(46.35±7.49)%and(1120.57±81.69)pg·mL^(-1),in the combination group and(52.47±7.87)%and(1338.62±84.73)pg·mL^(-1) in the control group,demonstrating that the differences were statistically significant(t=4.062,13.360,both P<0.001).The total incidence of clinically focused events in the combined group was 13.46%(7/52),which was remarkably lower than that of 26.92%(14/52)in the control(χ^(2)=7.675,P<0.05).Conclusion Compared to treatment with sacubitril valsartan sodium alone,the combined treatme

关 键 词：慢性心力衰竭 维立西呱 沙库巴曲缬沙坦钠 心电图 左心室射血分数 临床终点事件 

分 类 号：R541.6[医药卫生—心血管疾病]